EICHOR
● Recruiting
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Condition: Esophageal Adenocarcinoma · Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Sponsor: Weill Medical College of Cornell University
About this study
The goal of this study is to learn about of the research study drug, telomelysin (OBP-301), in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. The main question it aims to answer is whether this combination is safe and effective in this type of cancer. Participants will receive 5 injections of OBP-301, approximately every 2 weeks. OBP-301 will be injected directly into the tumor during an esophagogastroduodenoscopy (EGD). At the same time as the injection, a tumor biopsy will be taken. Participants will also receive pembrolizumab infusions every 6 weeks until disease progression or for a maximum of two years. Pembrolizumab infusions will occur on different days than OBP-301 injections.
This description comes directly from the study's public registry record.
Talk to the study team
Casey Owens · 646-962-6046 · cdo4001@med.cornell.edu
Myriam Elizaire-Williams · mye4001@med.cornell.edu
Always discuss trial participation with your own doctor first.
Locations (2)
| Weill Cornell Medicine/NewYork-Presbyterian Hospital | New York, New York, United States | Recruiting |
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06340711